Literature DB >> 18175971

Utility of some pi-acceptors for spectrophotometric determination of gatifloxacin in pure form and in pharmaceutical preparations.

Ayman Abouel Fetouh Gouda1, Ragaa El-Sheikh, Alaa Sayed Amin.   

Abstract

Four simple, quick and sensitive methods are described for the spectrophotometric determination of gatifloxacin. The methods are based on the reaction of gatifloxacin as n-electron donor with 7,7,8,8-tetracyanoquinodimethane (TCNQ); 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ); chloranilic acid (CLA) and p-chloranil (CL) as pi-acceptors to give highly colored complex species. The colored products are quantitated spectrophotometrically at 460, 841, 530 and 545 nm for DDQ, TCNQ, CLA and CL, respectively. Optimization of the different experimental conditions is described. Beer's law is obeyed in the concentration ranges 5-60, 1.5-18, 30-360 and 20-240 microg ml(-1) of gatifloxacin, but for more accurate analysis, Ringbom optimum concentration range was found to be 7.5-55, 3-16, 35-350 and 25-230 microg ml(-1) of gatifloxacin for DDQ, TCNQ, CLA and CL, respectively. The limits of detection and quantification were calculated and the relative standard deviations for different concentrations of gatifloxacin using various acceptors were <1.28%. The association constants of 1 : 1 complexes and standard free energy changes using Benesi-Hildebrand plots were studied. The proposed methods were successfully applied to the determination of gatifloxacin in pharmaceutical dosage forms without interference from common additives encountered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175971     DOI: 10.1248/cpb.56.34

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  1 in total

1.  Development and validation of stability-indicating high performance liquid chromatography method to analyze gatifloxacin in bulk drug and pharmaceutical preparations.

Authors:  Ibrahim A Aljuffali; Mohd Abul Kalam; Yasmin Sultana; Ahamad Imran; Aws Alshamsan
Journal:  Saudi Pharm J       Date:  2014-06-28       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.